BRIEF published on 03/30/2026 at 00:20, 1 month ago Barton Gold Receives $520,000 R&D Tax Refund Exploration Projects Barton Gold South Australia R&D Tax Incentive Gold And Silver Discoveries
BRIEF published on 03/30/2026 at 00:20, 1 month ago Barton Gold reçoit un remboursement de crédit d'impôt recherche et développement de 520 000 $ Projets D'exploration Barton Gold Australie Du Sud Découvertes D'or Et D'argent Incitation Fiscale À La R&D
BRIEF published on 03/29/2026 at 17:10, 1 month ago FAST III Trial Validates CAAS vFFR as a Competent Alternative to Wire-Based FFR Cardiovascular Care FAST III Trial CAAS VFFR Revascularization Non-Inferiority
BRIEF published on 03/29/2026 at 17:10, 1 month ago L'essai FAST III valide le CAAS vFFR comme une alternative compétente au FFR à fil. Soins Cardiovasculaires CAAS VFFR Essai FAST III Revascularisation Non-infériorité
BRIEF published on 03/29/2026 at 12:20, 1 month ago China XLX Reports 2025 Financial Results: Expansion and Strategic Focus Market Expansion Financial Strategy China XLX 2025 Results Fertilisers
BRIEF published on 03/29/2026 at 12:20, 1 month ago China XLX publie ses résultats financiers pour 2025 : expansion et orientation stratégique Stratégie Financière Expansion Du Marché Chine XLX Résultats 2025 Engrais
BRIEF published on 03/28/2026 at 18:39, 1 month 1 day ago US District Court Decision in TriZetto Re-trial Punitive Damages Atos Group US District Court TriZetto Re-trial Syntel And Cognizant
BRIEF published on 03/28/2026 at 18:39, 1 month 1 day ago Décision du tribunal de district américain dans le cadre du nouveau procès de TriZetto Groupe Atos Tribunal De District Des États-Unis Nouveau Procès De TriZetto Syntel Et Cognizant Dommages-intérêts Punitifs
BRIEF published on 03/28/2026 at 16:05, 1 month 1 day ago Sanofi's Amlitelimab Shows Promising Results in Phase 3 Atopic Dermatitis Studies Clinical Development Sanofi Atopic Dermatitis Phase 3 Studies Amlitelimab
BRIEF published on 03/28/2026 at 16:05, 1 month 1 day ago L'amlitelimab de Sanofi présente des résultats prometteurs dans les études de phase 3 sur la dermatite atopique Développement Clinique Sanofi Dermatite Atopique Études De Phase 3 Amlitelimab
Published on 04/30/2026 at 01:35, 2 hours 4 minutes ago Kalo Gold Provides Update on High-Resolution Airborne Magnetic Survey at Vatu Aurum Project, Fiji
Published on 04/30/2026 at 01:15, 2 hours 24 minutes ago Credissential Announces Shares Consolidation
Published on 04/30/2026 at 00:00, 3 hours 39 minutes ago Redwood AI CEO Highlights Role of its AI Technology Within Aidos-Led B.C. Government's Track and Trace Pilot Program on Conversations That Matter TV Series, Featured in the Vancouver Sun
Published on 04/29/2026 at 23:58, 3 hours 41 minutes ago Roxmore Announces Filing of Meeting Materials for Upcoming Shareholders Meeting
Published on 04/30/2026 at 03:05, 34 minutes ago Cohen & Steers Renames UCITS Preferred Securities Strategies as Hybrid Credit Strategies
Published on 04/29/2026 at 23:42, 3 hours 57 minutes ago H2APEX publishes figures for the 2025 financial year and provides positive outlook
Published on 04/29/2026 at 23:01, 4 hours 38 minutes ago Sirma Delivers 31% Revenue Growth in 2025 and Advances AI Platform Strategy
Published on 04/29/2026 at 22:15, 5 hours 24 minutes ago Amrize Grows Revenue 4.7% in First Quarter and Reaffirms 2026 Guidance
Published on 04/29/2026 at 22:05, 5 hours 34 minutes ago Evotec Announces New Nomination to Board of Directors
Published on 04/29/2026 at 18:15, 9 hours 24 minutes ago GUILLEMOT CORPORATION | MISE A DISPOSITION DU DOCUMENT D’ENREGISTREMENT UNIVERSEL INCLUANT LE RAPPORT FINANCIER ANNUEL 2025
